Amyloid oligomers in diabetic and nondiabetic human pancreas (Q46187387)

20 December 2017

title

Amyloid oligomers in diabetic and nondiabetic human pancreas (English)

1 reference

20 December 2017

0 references

1 reference

7

1 reference

20 December 2017

Juliana Chung-ngor Chan

10

1 reference

20 December 2017

author name string

Hai-Lu Zhao

1

1 reference

20 December 2017

Yi Sui

2

1 reference

20 December 2017

Jing Guan

3

1 reference

20 December 2017

Lan He

4

1 reference

20 December 2017

Xue-Mei Gu

5

1 reference

20 December 2017

Harriet Kt Wong

6

1 reference

20 December 2017

Fernand M M Lai

8

1 reference

20 December 2017

Peter C Y Tong

9

1 reference

20 December 2017

publication date

19 November 2008

1 reference

20 December 2017

published in

Translational Research

1 reference

20 December 2017

volume

153

1 reference

20 December 2017

issue

1

1 reference

20 December 2017

page(s)

24-32

1 reference

20 December 2017

Mechanism of thioflavin T binding to amyloid fibrils.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

Molecular mechanisms of amyloidosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

A century-old debate on protein aggregation and neurodegeneration enters the clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

Islet amyloid and type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

Co-localization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

Islet amyloid polypeptide plasma concentrations in individuals at increased risk of developing type 2 (non-insulin-dependent) diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

Role of islet amyloid polypeptide secretion in insulin-resistant humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

The aggregation potential of human amylin determines its cytotoxicity towards islet beta-cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

Inhibition of human IAPP fibril formation does not prevent beta-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

Islet amyloid: a complication of islet dysfunction or an aetiological factor in Type 2 diabetes?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): a new model for type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

Extensive islet amyloid formation is induced by development of Type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

Toxic human islet amyloid polypeptide (h-IAPP) oligomers are intracellular, and vaccination to induce anti-toxic oligomer antibodies does not prevent h-IAPP-induced beta-cell apoptosis in h-IAPP transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

Assessment of human pancreatic islet architecture and composition by laser scanning confocal microscopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

The unique cytoarchitecture of human pancreatic islets has implications for islet cell function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

A specific amyloid-beta protein assembly in the brain impairs memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

Role of islet amyloid in type 2 diabetes mellitus: consequence or cause?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

Impairment of the ubiquitin-proteasome pathway is a downstream endoplasmic reticulum stress response induced by extracellular human islet amyloid polypeptide and contributes to pancreatic beta-cell apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

Neurodegenerative disease: amyloid pores from pathogenic mutations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.10.009

10.1016/J.TRSL.2008.10.009

7 January 2021

Identifiers

DOI

1 reference

20 December 2017

PubMed ID

19100955

1 reference

20 December 2017